FinanceNews

Lincoln Pharma posts profit of Rs 11.85 crore of Rs 11.85 crore

Net revenue from operations in Q4FY21 was reported at Rs 77.54 crore

Lincoln Pharmaceuticals has reported a net profit of Rs 11.85 crore in Q4FY21 as against a net profit of Rs. 9.23 crore in the corresponding period last year, a growth of 28.33 per cent. Net revenue from operations in Q4FY21 was reported at Rs 77.54 crore, higher by 3.03 per cent over the previous fiscal’s same period net revenue from operations of Rs 75.26 crore. The company reported an EBITDA of Rs. 16.74 crore in Q4FY21, a rise of 28.25 per cent as compared to Rs 13.05 crore in the corresponding period last year. EPS for Q4FY21 was at Rs 5.92 per share as compared to Rs 4.62 in the corresponding period last year. The company has recommended a dividend of 15 per cent – Rs. 1.50 per share on the face value of Rs 10 per share.

THIS CAN BE YOUR ADVERTISEMENT

During the fiscal, the promoter group of Lincoln Pharmaceuticals increased holding in the company to 37.25 per cent – a rise of 4.9 per cent (490 bps) from 32.36 per cent as of 31 March 2020. The promoter group bought 9.8 lakh shares from the secondary market during the year. Backed by improvement in the company’s financial risk profile, steady growth in scale and margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.

Commenting on the results and performance, Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “The company’s performance during the quarter and a full year has been quite robust and considering that we have recommended a dividend of Rs. 1.50 per share. The company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in the coming years. Our strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term.”

The company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. It currently exports to more than 60 countries and plans to expand to 90 plus countries. For the next phase of growth, the company is building a strong portfolio in the lifestyle and chronic segment especially dermatology, gastro and pain management to complement its strong presence in the acute segment.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close